The timing of action potentials is an important determinant of information coding in the brain. The shape of the EPSP has a key influence on the temporal precision of spike generation. Here we use dynamic clamp recording and passive neuronal models to study how developmental changes in synaptic conductance waveform and intrinsic membrane properties combine to affect the EPSP and action potential generation in cerebellar granule cells. We recorded EPSCs at newly formed and mature mossy fiber-granule cell synapses. Both quantal and evoked currents showed a marked speeding of the AMPA receptor-mediated component. We also found evidence for age- and activity-dependent changes in the involvement of NMDA receptors. Although AMPA and NMDA receptors contributed to quantal EPSCs at immature synapses, multiquantal release was required to activate NMDA receptors at mature synapses, suggesting a developmental redistribution of NMDA receptors. These changes in the synaptic conductance waveform result in a faster rising EPSP and reduced spike latency in mature granule cells. Mature granule cells also have a significantly decreased input resistance, contributing to a faster decaying EPSP and a reduced spike jitter. We suggest that these concurrent developmental changes, which increase the temporal precision of EPSP-spike coupling, will increase the fidelity with which sensory information is processed within the input layer of the cerebellar cortex.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6740347PMC
http://dx.doi.org/10.1523/JNEUROSCI.23-14-06074.2003DOI Listing

Publication Analysis

Top Keywords

nmda receptors
16
granule cells
12
intrinsic membrane
8
membrane properties
8
temporal precision
8
developmental changes
8
changes synaptic
8
synaptic conductance
8
conductance waveform
8
epsp reduced
8

Similar Publications

Background: Arc is a synaptic immediate early gene that mediates two distinct pathways at excitatory synapses. Canonically, Arc accelerates endocytosis of AMPA receptors by direct binding to TARPgs and endocytic machinery and thereby contributes to mGluR-LTD. Arc also acts at recently potentiated synapses, where it is phosphorylated by CaMKII and binds NMDAR subunits NR2A and NR2B and recruits the PI3K adaptor p55PIK to assemble a signaling complex that activates AKT and inhibits GSK3β.

View Article and Find Full Text PDF

Developing Topics.

Alzheimers Dement

December 2024

Centre for Medical Image Computing, Department of Computer Science, University College London, London, United Kingdom.

Background: Neurotransmitter receptors' contribution to Alzheimer's disease (AD) pathology development has been implicated by basic science studies but is yet to be fully established. Here, we incorporate receptor density maps into network spreading models to predict amyloid and tau patterns in AD, reflecting their potential roles in facilitating or impeding pathology production and connectivity-mediated spread.

Method: Amyloid-PET positive individuals from the Alzheimer's Disease Neuroimaging Initiative (ADNI) were divided into "early" (n = 119) and "late" (n = 69) pathology groups according to tau accumulation in the temporal cortex (Figure 1A).

View Article and Find Full Text PDF

Developing Topics.

Alzheimers Dement

December 2024

Faculty of Medicine, Arish University, Arish, North Sinai, Egypt.

Background: Lingual taste cells (LTCs) are taste buds' sensory cells that modulate gustation. This study's aim is to assess whether it can be successfully implanted in hippocampus, modulating learning and memory deficits observed in Alzheimer's Dementia (AD).

Methods: Retrospective trials on rodents i.

View Article and Find Full Text PDF

Background: Chronic air pollution exposure increases accelerates cognitive aging and AD risk. Synapse loss in AD correlates with decreased cognitive ability. In rodents, inhaled air pollutants decreased glutamatergic synapses, decreasing excitatory postsynaptic currents (EPSCs), while increasing total levels of AMPA and NMDA receptor protein.

View Article and Find Full Text PDF

Drug Development.

Alzheimers Dement

December 2024

Axsome Therapeutics, New York, NY, USA.

Background: Patients with Alzheimer's disease (AD) often experience burdensome neuropsychiatric symptoms, including agitation which occurs in both home and long-term care (LTC) facilities, and is associated with substantial increases in caregiver burden and LTC placements. AXS-05 (45-mg dextromethorphan/105-mg bupropion), a novel, oral NMDA receptor antagonist and sigma-1 receptor agonist, approved by the FDA for major depressive disorder, is being investigated for treatment of AD agitation (ADA). AXS-05 has been evaluated in 2 randomized, double-blind studies: Phase 2 ADVANCE-1 (NCT03226522); Phase 3 ACCORD (NCT04797715).

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!